Home » Newsletters » BioWorld Science

BioWorld Science

June 9, 2010

View Archived Issues

Irinotecan/S-1 active in 5-FU-resistant bladder cancer cell lines

Fast-dissolving desmopressin is safe in adults with nocturia

Two placebo-controlled trials show safety of CX-157

New GABA(A) receptor modulators claimed by NeuroSearch

Merck & Co. discloses new FABP inhibitors

Merck & Co. describes new gamma-secretase modulators

Nycomed presents new PDE4B inhibitors

Arbaclofen placarbil improves sleep quality in PPI-responsive GERD

Antitumor agent MSC-1936369B shows safety in phase I trial

NTx described as biomarker for prediction of bone metastasis in lung cancer

Bortezomib linked to heart failure in patients with multiple myeloma

PTC receives award to develop anticancer drugs targeting BMI-1

Merck Serono resubmits cladribine tablets NDA for relapsing MS to FDA

Benlysta MAA submitted to EMA for SLE

Can-Fite opens new CF-101 IND with phase II/III trial protocol in psoriasis

VIVUS' avanafil improves ED in phase III trial in diabetic men

Auxilium reports 2-year recurrence data on Xiaflex

AVI BioPharma and DTRA enter into new contract for AVI-7100

Phico Therapeutics' PT1.2 safe and well tolerated in phase I trial

Zealand Pharma and sanofi-aventis extend lixisenatide licensing agreement

Telik reports phase II data on ezatiostat in MDS

Adeona advances enrollment in part 2 of CopperProof-2 trial in AD

Immunovaccine and Vaxil join to advance potential cancer vaccine

Cellceutix expedites studies of KM-391 and Kevetrin

Opal Therapeutics and MGH to jointly develop HIV vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...